Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer
The Oncologist · 02.02.2024 · 29 (2) · 100-101
DOI: 10.1093/oncolo/oyad202 ↗Kurz gefasst
Editorial in der Zeitschrift The Oncologist, online erschienen am 08.09.2023. Verfasst von David J Benjamin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hoag Family Cancer Institute, Newport Beach, CA, USA. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Highlighting concerns about the acceptance of oncologic therapies with no proven benefit, this article compares the interpretation of the clinical trial results of several studies conducted to identify a better therapy for patients with biliary tract cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hoag Family Cancer Institute, Newport Beach, CA, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
ORCID-Profile: David J Benjamin
Zitieren
APA
Benjamin, D. J., & Prasad, V. (2024). Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer. The Oncologist, 29(2), 100-101. https://doi.org/10.1093/oncolo/oyad202
Vancouver
Benjamin DJ, Prasad V. Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer. The Oncologist. 2024;29(2):100-101. doi:10.1093/oncolo/oyad202
BibTeX
@article{Benjamin2024,
author = {Benjamin, David J and Prasad, Vinay},
title = {Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {2},
pages = {100--101},
doi = {10.1093/oncolo/oyad202}
}
EUVIMED